Regeneron Pharmaceuticals has come out with a drug known as IL-1 Trap which can be effectively used for treatment of CAPS or CIAS1-related autoinflammatory periodic syndromes. It is regarded as a rare inherited spectrum of inflammatory conditions and the symptoms of this disease are spontaneous systemic inflammation. People suffering from this disease get the inflammation when they get exposed to cold temperatures. Regeneron is looking forward to get the approval from FDA in the second quarter of 2007 after the open label extension study is completed. Already the drug has got orphan drug status and this status is granted in case of only those drugs which are being developed for treating rare diseases.